WO2012175027A1 - Methods of mutagenesis of schizochytrium sp and variant strains produced thereof - Google Patents

Methods of mutagenesis of schizochytrium sp and variant strains produced thereof Download PDF

Info

Publication number
WO2012175027A1
WO2012175027A1 PCT/CN2012/077285 CN2012077285W WO2012175027A1 WO 2012175027 A1 WO2012175027 A1 WO 2012175027A1 CN 2012077285 W CN2012077285 W CN 2012077285W WO 2012175027 A1 WO2012175027 A1 WO 2012175027A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
schizochytrium
variant
dha
naive
Prior art date
Application number
PCT/CN2012/077285
Other languages
English (en)
French (fr)
Inventor
Bernard Pora
Jie Zhou
Original Assignee
Roquette Freres
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roquette Freres filed Critical Roquette Freres
Priority to KR1020137033914A priority Critical patent/KR20140019840A/ko
Priority to CN201280029881.9A priority patent/CN103827289B/zh
Priority to JP2014516178A priority patent/JP5894666B2/ja
Publication of WO2012175027A1 publication Critical patent/WO2012175027A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A23L17/60—Edible seaweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor
    • C12N1/125—Unicellular algae isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/89—Algae ; Processes using algae

Definitions

  • the application relates to microbial genetic breeding technology and biological fermentation technology, particularly, a variant or mutant strain of microalgae for producing DHA (Docosahexaenoic acid).
  • DHA Docosahexaenoic acid, C22:6, (omega-3)
  • DHA is an essential fatty acid, i.e. a long-chain fatty acids which cannot be synthesized in human body and has important physiological functions.
  • DHA is a main component in human brain and retina. 20% of the total DHA is present in cerebral cortex and up to 50% in retina. Therefore, it plays an important role in development of nervous system and visual system, and maintenance of normal intelligence and vision function.
  • DHA also has physiological functions in prevention of cardiovascular diseases, cancers, inflammation, etc.
  • it is also an essential fatty acid required by a variety of marine fishes for growth and development, and it can improve the survival rate of fish fries and reduce the incidence of albinism.
  • DHA is obtained from fish oil.
  • Schizochytrium sp. is a marine microalgae (or pseudo-fungi) that has been developed as a commercial source for producing DHA and other polyunsaturated fatty acids (PUFAs). The biosafety of Schizochytrium sp. has been verified. Hammond et al. performed a series of tests with it on rats and rabbits, and found no side effects.
  • Acetyl-CoA carboxylase (ACC, (EC 6.4.1.2) is a key enzyme in fatty acid synthesis, and herbicide Quizalofop ⁇ 2-[4-(6-chloro-2-Quinoxaline-oxy)-phenoxy] propionate ⁇ is an inhibitor of this enzyme. In the presence of Quizalofop, cells grow slowly or even die due to the disturbed fatty acid biosynthesis.
  • a Schizochytrium sp. variant or mutant with increased DHA content can be obtained by applying a mutagenesis of UV radiation to a Schizochytrium sp. strain and then performing a directional selection by using an inhibitor to the key enzyme in fatty acid synthesis (such as acetyl coenzyme A carboxylase), including but not limited to Quizalofop. Further, the obtained variants or mutants have high DHA contents, as well as improved growth rates compared with a naive Schizochytrium sp. strain.
  • a method for producing a variant of Schizochytrium sp. strain having increased DHA content compared with a naive Schizochytrium sp. strain comprising inducing mutagenesis in a Schizochytrium sp. strain with UV radiation to produce a mutant strain; contacting the mutant strain with an acetyl coenzyme A carboxylase inhibitor; and selecting a variant of Schizochytrium sp. strain having increased DHA content compared with a naive Schizochytrium sp. strain.
  • the inhibitor to acetyl coenzyme A carboxylase is Quizalofop.
  • the selected variant having increased DHA content also has improved growth rate compared with that of a naive Schizochytrium sp. strain so that the efficiency of DHA production is increased compared with that of a naive Schizochytrium sp. strain.
  • the variant of Schizochytrium sp. strain has higher DHA content as compared with that of its starting strain or a naive Schizochytrium sp. strain.
  • the variant of Schizochytrium sp. strain has higher DHA content as compared with that of the starting or naive strain after UV radiation-induced mutagenesis with or without the selection by using an inhibitor to acetyl coenzyme A carboxylase.
  • a variant of Schizochytrium sp. strain such as strain 2010-0321 with a deposit reference number of CCTCC M 2011024 as deposited at the Chinese Center for Type Culture Collection (CCTCC) on January 21, 2011.
  • the variant strain provided herein has increased DHA content compared with that in a naive Schizochytrium sp. strain.
  • the variant provided herein is obtained by the method as disclosed herein comprising inducing mutagenesis in a Schizochytrium sp. strain with UV radiation to produce a mutant strain, and contacting the mutant strain with an acetyl coenzyme A carboxylase inhibitor; and selecting a variant of the Schizochytrium sp. strain having increased DHA content and/or improved growth rate compared with a naive Schizochytrium sp. strain.
  • a method for producing DHA comprising culturing a variant of Schizochytrium sp. strain as disclosed herein in a culture medium, and optionally comprising collecting DHA from a biomass of the cultured variant of Schizochytrium sp. strain, or a culture medium thereof. According to an embodiment, it is also related to biomass produced by this method.
  • the food product contains the biomass (i.e. having increased concentration of DHA compared with a naive Schizochytrium sp. strain) or DHA produced according to the method disclosed herein.
  • Figure 1 shows lethal effects of ultraviolet radiation on Schizochytrium sp.
  • Figure 2 shows the relationship between the concentration of Quizalofop and corresponding lethality rate of Schizochytrium sp..
  • Figure 3 shows the growth rates and DHA contents of a control strain (or a naive strain) and some variant strains.
  • Figure 4 shows the growth rates and DHA contents of a control strain and three variants in a 50-liter fermentor experiment.
  • Figure 5 shows alignment comparison of 18S rRNA sequences between a control strain and variant strain 2010-0321.
  • strain refers to any culture, generally pure culture, of a microorganism such as algae or microalgae species including a Schhochytrium sp. strain obtained from a single cell or an isolated colony.
  • the term 'Variant or “mutant” of a reference strain X refers to any strain obtained from the reference strain X.
  • the term “variant” more particularly refers to a strain obtained mainly by mutation and selection performed on a reference strain X
  • the term “mutant” more particularly refers to a strain obtained by random or directed mutagenesis (for example UV radiation) applied to a reference strain X.
  • mutant or variant possesses the features according to various aspects disclosed herein, particularly a higher or increased DHA content compared with a naive algae or microalgae species, particularly a Schizochytrium sp. strain, it falls within the protection scope claimed in the application.
  • food product refers to any product intended for supplying human or animals with nutrition.
  • food products include products intended for feeding infants, children, adolescents and adults. All or part of the food products disclosed herein may contain at least one biomass or DHA obtained by the method disclosed herein.
  • the food products disclosed herein may also contain other ingredients usually used in the agriculture or food industry, such as additives, preservatives, fruits or fruit extracts, flavouring agents, colorants, thickeners, cereals, chocolate, etc.
  • the food product is a dairy product.
  • the term "dairy product” refers to, in addition to milk, any product derived from milk, such as, milk powder, cream, ice cream, butter, cheese, yogurt, fermented milk, or by-products derived from milk, such as lactoserum and casein as well as various prepared food products containing milk or milk fractions as main ingredient.
  • the milk is generally from cows, but can also be obtained from other mammals, such as a goat, a ewe, a mare, a camel or a buffalo.
  • the dairy products incorporate the biomass or DHA produced according to the method disclosed herein.
  • Microorganisms suitable for serving as a starting strain or a naive/control strain for the mutation mutagenesis and/or selection disclosed herein include heterotrophic microalgaes, including members of the genus Schizochytrium.
  • a particular member of the genus Schizochytrium is Schizochytrium limacinum.
  • Suitable organisms can be obtained from a number of public-available sources, including by collection from the natural environment.
  • Schizochytrium sp. which can be used in the present application includes Schizochytrium limacinum SR21, Schizochytrium sp. (S8) (ATCC 20889), Schizochytrium sp.
  • LC- M (ATCC 18915) and Schizochytrium limacinum IFO 32693 (Honda et Yokochi, Institute for Fermentation (IFO), Osaka, Japan).
  • Schizochytrium limacinum SR21 or Schizochytrium limacinum IFO 32693 is preferred.
  • any microorganism or any specific type of organism includes wild-type strains, mutant strains or recombinant strains.
  • biomass refers to a culture or cells in culture medium of algae or microalgae species, such as a Schizochytrium sp. strain, a variant of a Schizochytrium sp. strain, etc. as disclosed herein.
  • biomass refers to at least partially dewatered algal or microalgal culture, or dewatered culture.
  • the term “about” or “approximately” when used in conjunction with a numerical value refers to any value within 1, 5 or 10% variability of the referenced number.
  • a Schizochytrium sp. strain is exposed to ultraviolet radiation for about 10 to 140 sec (s), preferably about 20s to 120s, more preferably about 30s to 100s, and most preferably about 70s to 90s.
  • a Schizochytrium sp. strain is exposed to ultraviolet radiation for a period of time selected from the group consisting of about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 and 90 seconds.
  • the survived colonies are collected and used in the directional selection by an acetyl coenzyme A carboxylase inhibitor, such as Quizalofop.
  • Quizalofop is added to a culture medium at a certain concentration in order to select a Quizalofop-resistant strain.
  • concentration of Quizalofop used in the selection is in the range of about 5 ⁇ /L to about 100 ⁇ /L, or about 10 umol/L to about 90 umoVL, or about 50 ⁇ /L to 80 ⁇ /L in a culture medium.
  • the concentration of Quizalofop is selected from the group consisting of about 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 and 80 ⁇ /L in a culture medium.
  • Quizalofop is Quizalofop-p
  • the selection for Quizalofop-resistant Schizochytrium sp. colonies is conducted in a solid culture medium containing Quizalofop. Then, survived colonies are picked out from the solid culture medium and subsequently cultured in a liquid or semi-solid culture medium containing Quizalofop to verify the Quizalofop resistance.
  • the selected Quizalofop-resistant colonies are further screened for increased growth rate and DHA content compared with a naive strain such as a Schizochytrium sp. strain.
  • the Schizochytrium sp.variants obtained by the method disclosed herein comprising UV exposure and Quizalofop selection can produce a higher or increased amount of DHA as compared with a starting or naive Schizochytrium sp.strain.
  • the Schizochytrium sp.variants obtained by the method disclosed herein comprising UV exposure and Quizalofop selection can produce a higher or increased amount of DHA as compared with a starting or naive Schizochytrium sp.strain.
  • variant can produce an amount of DHA higher than that produced by the starting or naive strain by at least about 10, 20, 25, 30, 35, 40%, or by at least about 20, 25, 30, 35, 40, 41, 42, 43, 44, 45,46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70% in a 3 to 7-day, or a 5-day culture or biomass.
  • the amount of DHA produced by the Schizochytrium sp In an embodiment, the amount of DHA produced by the Schizochytrium sp.
  • the growth rate of the selected Schizochytrium sp. variants are higher than those of the starting or naive strains by at least about 3, 4, 5, 6, 7, 8, 9 or 10%, preferably over a 3 to 7-day culture, more preferably over a 5-day culture.
  • the selected Schizochytrium sp. variant strains have stable growth rate and ability to produce DHA at a high amount under different culture conditions, such as different concentrations of glucose, different nitrogen sources and different pH values as compared with those of the starting or naive strains.
  • the 18S RNA of the Schizochytrium sp. variants can be analyzed to identify genetic variations as compared to the starting or naive strains.
  • examples of the Schizochytrium sp. variants comprise but not limited to strains 321-1, 2010-0321, and 303-11, particularly strain 2010-0321.
  • a Schizochytrium sp. variant disclosed herein particularly a strain selected from the group consisting of strains 321-1, 2010-0321, 303-11, and any combination thereof, or strain 2010-0321, is cultured under a cultivation condition suitable for culturing Schizochytrium sp. strains.
  • the cultivation conditions may be established according to culturing methods well-known in the art, including the methods disclosed in U. S. Patent No. 5,130, 242 and U. S. Patent No. 7,022,512, which are incorporated herein by reference in their entirety, and optimal cultivation conditions may be readily determined by those skilled in the art.
  • cultivation may be carried out in any suitable fermentor, such as a stirred tank fermentor or an air-lift fermentor which provides oxygen source.
  • the microorganisms can be agitated at a certain level, such that the concentration of dissolved oxygen is sufficient to support the growth of the culture and production of DHA, and at the same time the agitation does not shear or otherwise damage the microorganisms.
  • Suitable level of dissolved oxygen is at least 10% of air saturation level. More particularly, level of dissolved oxygen is maintained from about 10% to about 50% of air saturation levels.
  • An exemplary fermentor used in the method disclosed herein may provide an aeration rate of 1 WM with a rotating speed of about 70-100 rpm.
  • the capacity of the fermentor is at least 10-60 liters, such as 10, 20, 30, 40, 50 or 60 liters.
  • a fermentor with the capacity of up to 100 or even 150 liters can be used.
  • Cultivation may be carried out at any temperature suitable for maintaining the survival of microorganisms.
  • microorganisms may be cultured at a temperature from about 15°C to about 34°C.
  • the cultivation temperature is maintained at about 20°C to about 28°C, more preferably about 22°C to about 27°C.
  • the pH of the culture medium during fermentation can be from 4 to 10, such as from 5 to 8, preferably from 6 to 7.
  • the fermentation will last for 10 days or less, or 9 days or less, or 8 days or less.
  • the fermentation duration may be or be at least 3, 4, 5, 6 or 7 days.
  • the fermentation duration may be 150 to 200 hours, such as 160 to 190 hours, or from 170 to 180 hours.
  • medium used in the method for culturing the Schizochytrium sp. variants disclosed herein is a liquid medium, which may comprise the components that can promote growth and production of DHA at commercially practicable scales, including those components disclosed in U. S. Patent No. 5,130, 242 and U. S. Patent No. 7,022, 512, all of which are incorporated herein by reference in their entirety.
  • the medium used for culturing the Schizochytrium sp. variants disclosed herein to produce DHA comprise a carbon source, and an organic or inorganic nitrogen source.
  • the carbon source comprises glucose, various starches, molasses, ground corn or a combination thereof.
  • the nitrogen source may include but not limited to nitrate, urea, ammonium salts, amino acids, yeast extracts and the like.
  • An assimilable phosphorous (e.g. phosphate) and/or sulphur (e.g. sulphate) source may also be provided in the medium.
  • the medium may additionally contain other substances to facilitate the fermentation, for example a chelating agent (e.g. citric acid), an anti-foaming agent (e.g. soy bean oil), a vitamin (e.g. thiamine and or riboflavin), essential catalytic metals (for example, alkali earth metals such as magnesium or calcium, or zinc or iron and/or other metals such as cobalt and copper).
  • a chelating agent e.g. citric acid
  • an anti-foaming agent e.g. soy bean oil
  • a vitamin e.g. thiamine and or riboflavin
  • essential catalytic metals for example, alkali earth metals such as magnesium or calcium, or zinc or iron and/or other metals such as cobalt and copper.
  • the medium also may contain a source of microbial growth factors, which are unspecified or specified compounds that can enhance the heterotrophic growth of unicellular microorganisms.
  • Exemplary medium for culturing Schizochytrium sp. may be found in Jiang and Chen, Process Biochemistry 35 (2000) 1205-1209; Jiang and Chen, Journal of Industrial Microbiology & Biotechnology, (1999) Vol. 23,508-513 ; Vazhappilly and Chen, Journal of the American Oil Chemists Society, (1998) Vol. 75, No. 3 p 393-397.
  • the medium used in the method disclosed herein contains glucose 40-60, yeast extract 10-15, glutamic acid 4-8, sodium chloride 2.4-4.0, bitter salt 3.0-6.0, and ammonia sulfate 3.0-6.0 (g/L medium).
  • the medium used in the methods disclosed herein consists of glucose 40-60, yeast extract 10-15, sodium glutamate 4-8, sodium chloride 2.4-4.0, bitter salt 3.0-6.0, and ammonia sulfate 3.0-6.0 (g L medium).
  • An example of the medium used herein consists of glucose 60.0, yeast extract 15.0, sodium glutamate 4.0, sodium chloride 3.0, bitter salt 5.0, and ammonia sulfate 5.0 (g L medium).
  • the organisms or biomass may be harvested by means, such as centrifugation, flocculation, or filtration, and can be processed immediately or dried for future processing.
  • lipids can be extracted.
  • the term "lipid” includes phospholipids; free fatty acids; esters of fatty acids; triacylglycerols; diacylglycerides; monoacylglycerides; lysophospholipids; soaps; phosphatides; sterols and sterol esters; carotenoids; xanthophylls (e.g., oxycarotenoids); hydrocarbons; and other lipids known to one of ordinary skill in the art.
  • DHA disclosed herein can be in the form of these various lipids, and is not limited to a free fatty acid, which may be a form in the food product disclosed herein. Different forms or fractions of the lipids can be extracted, depending on the extraction technique that is used.
  • Lipids can be extracted with an effective amount of solvent.
  • suitable solvents used in the extraction polar lipids (e.g., phospholipids) are generally extracted with polar solvents (e.g., chloroform/methanol), and neutral lipids (e.g., triacylglycerols) are generally extracted with non-polar solvents (e.g., hexane).
  • a particular solvent is pure hexane.
  • a suitable ratio of hexane to dry biomass is about 4 liters of hexane per kilogram of dry biomass.
  • hexane is mixed with the biomass in a stirred reactor at a temperature of about 50°C for about 2 hours.
  • the biomass is filtered and separated from the oil-containing hexane.
  • Hexane is removed from the oil by distillation techniques.
  • Conventional oilseed processing equipment is suitable to perform the filtering, separation and distillation. Additional processing steps can be performed if required or desirable for a particular application.
  • Schizochytrium limacimim SR21 which was also used as a control or naive strain in the following Examples, was plated onto dishes, and exposed to UV radiation for 0 sec (control), 30 sec, 40 sec, 50 sec, 60 sec, 70 sec, 80 sec, 90 sec and 100 sec (experimental groups), respectively. After radiation, the dishes were kept in dark for 24h, and the numbers of colonies on each dish was counted. The number of colonies in the control group was defined as 100%, and a lethality rate in each experimental group was calculated accordingly (Figure 1). As shown in Figure 1, with prolonged radiation duration, higher lethality rate was observed in Schizochytrium sp., indicating a dose-dependent effect. Particularly, a radiation duration of 70-90 sec, which resulted in a lethality rate of 60%-80% in Schizochytrium sp., was used to induce mutagenesis in Schizochytrium sp..
  • the culture conditions are: A. culture medium consisting of
  • Quizalofop ethyl was added into the medium for culturing Schizochytrium sp. at a concentration of 0 umol/L, 10 ⁇ mol/L, 30 ⁇ L, 50 ⁇ /L, 70 ⁇ L, 80 ⁇ /L and 90 umol/L.
  • the number of colonies in the control group (0 ⁇ /L) was defined as 100%. Colonies in each group were counted, and the lethality rates were calculated based on the number of colonies in the control group ( Figure 2). As shown in Figure 2, within the experimental range, a positive correlation between the lethality rates of Schizochytrium sp. and the concentrations of Quizalofop was observed.
  • the concentration of Quizalofop used for selecting resistant strains was set to 50 ⁇ L to 80 ⁇ L.
  • the selected strains may be cultured in a liquid or semi-solid Quizalofop-containing medium to validate their Quizalofop resistance.
  • the culture conditions are:
  • A. culture medium consisting of
  • Example 3 Differences between naive strains and variant strains in growth rate and DHA content
  • the culture conditions are:
  • A. culture medium consisting of
  • Figure 3 shows the biomass and DHA content of the control strain (left most) and some of the variants which underwent UV mutagenesis followed by Quizalofop selection.
  • some of the mutant strains had growth rate and the DHA content lower than that of the control strain, e.g. 321-6, 321-7 and 321-8, and some had growth rate and the DHA content not significantly different from that of the control strain, e.g. 321-4 321-5 and 321-19.
  • many of them had increased DHA content, e.g. 321-1, 2010-0321, 321-12, 321-13, 321-14, 321-15, 321-16, 321-17 and 321-18.
  • the outstanding strains are 321-1 and 2010-0321, which had growth rate increased by 10.5% and 31.5%, and DHA content increased by 64.5% and 66.4%, respectively.
  • mutant strain 303-11 In addition to these two mutant strains, mutant strain 303-11 also showed good growth rate and DHA content.
  • strains 2010-0321, 321-1 and 303-11 were selected for the tests as described in Examples 4-7 to verify that the variants obtained by the method of the application had the properties of high DHA content and growth rate, and the above properties could be stably maintained under different culture conditions.
  • A. culture medium consisting of
  • Example 4 The growth rates and DHA contents of the control strain and strains 321-1, 2010-0321 and 303-11 cultured under different concentrations of glucose.
  • the culture conditions are the same as those in the general conditions as described above.
  • g L.d weight of biomass per liter of medium per day.
  • w/w% percentage of weight of DHA based on weight of dry cells.
  • Example 5 Growth rate and DHA content of the control strain and strains 321-1, 20104)321 and 303-11 cultured in different nitrogen sources
  • the culture conditions are the same as the general conditions as described above.
  • the Example was conducted to compare the growth rate and DHA content of the control (naive) strain and mutant strains 321-1, 2010-0321 and 303-11 cultured in different nitrogen sources.
  • the nitrogen source in the initial medium was replaced by following nitrogen sources: (a) Yeast extract (20 g L); (b) Yeast extract (20 g L)+Sodium glutamate (10 g LXc) Yeast extract(40 g L)+Sodium glutamate (10 g/L), and (d) Corn syrup(40 g/L)+Sodium glutamate (10 g L).
  • mutant strains 321-1 and 2010-0321 were superior to those of the control strain, in which strain 2010-0321 was better than strain 321-1 in DHA content, while strain 303-11 showed a higher DHA content as compared to the control strain.
  • w/w% percentage of weight of DHA based on weight of dry cells.
  • Example 6 Growth rate and DHA content of the control strain and strains 321-1, 2010-0321 and 303-11 cultured under different pH values
  • the culture conditions are the same as those in the general conditions as described above.
  • g L.d weight of biomass per liter of medium per day.
  • w/w% percentage of weight of DHA based on weight of dry cells.
  • Example 7 Growth rate and DHA content of the control strain and strains 321-1, 2010-0321 and 303-11 cultured in 50-L fermentors
  • Example 7 was conducted to assess the growth rate and DHA accumulation of the control (naive) strain and strains 321-1, 2010-0321 and 303-1 Icnltured in 50-L fermentors ( Figure 4).
  • the strains were cultured under the general conditions as described above.
  • strain 321-1 showed biomass increased by 9.5% and DHA content increased by 16.7%, respectively.
  • strain 2010-0321 the biomass and DHA content increased by 6.7% and 48.1%, respectively.
  • the biomass was substantially the same as the control strain, and the DHA content increased by only 7.9%.
  • 2010-0321 was most prominent, particularly in term of DHA content.
  • Table 4 and Table 5 showed the differences between the control (naive) strain and strain 2010-0321 in biochemical composition, including the composition of proteins, amino acids and fatty acids.
  • the content of proteins was determined by Kjeldahl method.
  • the content of amino acids was assayed by an amino acid analyzer.
  • the content of fat was analyzed by a lipid analyzer.
  • strain 2010-0321 had protein content (23.8%) higher than mat of the control strain (22.3%). Consistently, strain 2010-0321 showed a higher level than the control strain in term of the content of most of the amino acids.
  • strain 2010-0321 had remarkable differences from the control strain in the composition of fatty acids. Firstly, strain 2010-0321 had C16:0 content (8.2%) higher than that of the control strain (7.7%). Secondly, CI 6:1 was absent in 2010-0321, while the CI 6:1 content of the control strain was 1.0%. Thirdly, strain 2010-0321 had DHA (C22:6) content significantly higher than that of the control strain.
  • the 18S rRNA gene of the control strain (SEQ ID NO: 1) is 1757 bp in length, while the 18S rRNA gene of strain 2010-0321 (SEQ ID NO: 2) is 1751 bp in length, in which 9 base pairs varied.
  • the percent homology between the 18S rRNA gene of the control strain and that of strain 2010-0321 was 99%.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/CN2012/077285 2011-06-23 2012-06-21 Methods of mutagenesis of schizochytrium sp and variant strains produced thereof WO2012175027A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020137033914A KR20140019840A (ko) 2011-06-23 2012-06-21 스키조키트리움 종의 돌연변이유발 방법 및 이의 생성되는 변이체 균주
CN201280029881.9A CN103827289B (zh) 2011-06-23 2012-06-21 裂殖壶菌诱变方法及其产生的变异株
JP2014516178A JP5894666B2 (ja) 2011-06-23 2012-06-21 シゾキトリウム属（Ｓｃｈｉｚｏｃｈｙｔｒｉｕｍ ｓｐ．）の突然変異誘導の方法及びそれから産生された変異体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110176833XA CN102839129A (zh) 2011-06-23 2011-06-23 一种裂殖壶菌诱变方法及其产生的变异株
CN201110176833.X 2011-06-23

Publications (1)

Publication Number Publication Date
WO2012175027A1 true WO2012175027A1 (en) 2012-12-27

Family

ID=47366849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/077285 WO2012175027A1 (en) 2011-06-23 2012-06-21 Methods of mutagenesis of schizochytrium sp and variant strains produced thereof

Country Status (4)

Country Link
JP (1) JP5894666B2 (ja)
KR (1) KR20140019840A (ja)
CN (3) CN102839129A (ja)
WO (1) WO2012175027A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001736A1 (fr) * 2013-02-06 2014-08-08 Roquette Freres Biomasse de la microalgue schizochytrium mangrovei et son procede de preparation
EP2947141A4 (en) * 2013-01-18 2016-08-10 Kyowa Hakko Bio Co Ltd MICRO-ORGANISMS FOR THE PREPARATION OF DOCOSAHEXAENIC ACIDS AND USE THEREOF
FR3038914A1 (fr) * 2015-07-17 2017-01-20 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
FR3038913A1 (fr) * 2015-07-17 2017-01-20 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
CN108587916A (zh) * 2018-05-23 2018-09-28 昆明理工大学 一种共培养单针藻在中性条件下快速絮凝的方法
WO2022124482A1 (ko) * 2020-12-07 2022-06-16 씨제이제일제당(주) 단일 미세조류로부터 단백질 및 오메가-3 지방산을 포함하는 바이오매스를 제조하는 방법 및 이에 의해 제조된 바이오매스

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450529A (zh) * 2013-09-25 2015-03-25 郭星 一种裂殖壶菌菌株及其诱变方法和应用
CN104312929B (zh) * 2014-10-27 2017-10-17 山东百龙创园生物科技股份有限公司 一株高产dha裂殖壶菌菌株及其培养方法与应用
FR3031984B1 (fr) * 2015-01-27 2019-05-24 Roquette Freres Procede d'enrichissement de la biomasse de microalgues du genre traustochytrium en dha et en acides amines arg et glu
CN105558305B (zh) * 2015-12-10 2019-12-03 新奥科技发展有限公司 裂殖壶菌突变株及其应用
CN108220167A (zh) * 2018-04-10 2018-06-29 中盐工程技术研究院有限公司 盐藻纯化分离方法及微藻纯化分离方法
CN108707630B (zh) * 2018-06-12 2020-10-16 厦门大学 一种提高裂殖壶菌中epa含量的调控方法与应用
CN112481348A (zh) * 2019-09-11 2021-03-12 天津大学青岛海洋技术研究院 一种高产dha裂殖壶菌突变菌株的筛选方法
CN111235035A (zh) * 2019-12-30 2020-06-05 嘉必优生物技术（武汉）股份有限公司 一种裂殖壶菌突变株及其用于制备二十二碳六烯酸油脂的方法和应用
CN114164122B (zh) * 2021-12-02 2023-06-20 嘉必优生物技术（武汉）股份有限公司 一种高产epa的裂殖壶菌及其应用
CN114621983B (zh) * 2022-05-13 2022-08-16 南京师范大学 提高裂殖壶菌的dha产量的方法和微生物油脂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591617A (zh) * 2009-06-15 2009-12-02 南京工业大学 一种二十二碳六烯酸生产菌株及其诱变筛选方法和其应用
CN101892160A (zh) * 2010-01-06 2010-11-24 吉林省希玛生物科技有限公司 一种海洋真菌裂殖壶菌(Schizochytrium)LX0809及其工业应用
CN101914581A (zh) * 2010-07-27 2010-12-15 南京工业大学 一种提高多烯不饱和脂肪酸发酵产量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264967C (zh) * 2004-12-08 2006-07-19 中国海洋大学 海洋真菌裂殖壶菌ouc88的工业应用
JP4344827B2 (ja) * 2005-11-28 2009-10-14 国立大学法人九州大学 スキゾキトリウム属の微生物を用いた長鎖高度不飽和脂肪酸含有リン脂質の製造方法
US9023616B2 (en) * 2006-08-01 2015-05-05 Dsm Nutritional Products Ag Oil producing microbes and method of modification thereof
KR20080111586A (ko) * 2007-06-19 2008-12-24 이정열 Schizochytrium mangrovei MM103을 이용한 Docosahexanoic acid(DHA)의 생산 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101591617A (zh) * 2009-06-15 2009-12-02 南京工业大学 一种二十二碳六烯酸生产菌株及其诱变筛选方法和其应用
CN101892160A (zh) * 2010-01-06 2010-11-24 吉林省希玛生物科技有限公司 一种海洋真菌裂殖壶菌(Schizochytrium)LX0809及其工业应用
CN101914581A (zh) * 2010-07-27 2010-12-15 南京工业大学 一种提高多烯不饱和脂肪酸发酵产量的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENG CHEN: "Study on producing DHA by fermentation with Schizochytrium limacinum SR21", CHINESE MASTER'S THESES FULL-TEXT DATABASE (ENGINEERING SCIENCE AND TECHNOLOGY 1), no. 2, 15 August 2007 (2007-08-15) *
DATABASE GENBANK 10 August 2010 (2010-08-10), LI,Q.: "Schizochytrium limacinum isolate OUC101 18S ribosomal RNAgene, partial sequence", accession no. M042905 *
KAIMIN CAI: "Mutation breeding ofSchizochytrium limacinum and optimization of its fermentation conditions", CHINESE MASTER'S THESES FULL-TEXT DATABASE (ENGINEERING SCIENCE AND TECHNOLOGY I), 15 September 2008 (2008-09-15) *
WEI PING ET AL.: "Effect of reinforcing acetyl-CoA supply in docosahexaenoic acid production by chizochytrium sp.", CHINA BIOTECHNOLOGY, vol. 31, no. 4, 26 April 2011 (2011-04-26), pages 87 - 91 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2947141A4 (en) * 2013-01-18 2016-08-10 Kyowa Hakko Bio Co Ltd MICRO-ORGANISMS FOR THE PREPARATION OF DOCOSAHEXAENIC ACIDS AND USE THEREOF
US10023884B2 (en) 2013-01-18 2018-07-17 Kyowa Hakko Bio Co., Ltd. Microorganism producing docosahexaenoic acid and utilization thereof
FR3001736A1 (fr) * 2013-02-06 2014-08-08 Roquette Freres Biomasse de la microalgue schizochytrium mangrovei et son procede de preparation
WO2014122158A1 (fr) * 2013-02-06 2014-08-14 Roquette Freres Biomasse de la microalgue schizochytrium mangrovei et son procédé de préparation
US9816116B2 (en) 2013-02-06 2017-11-14 Roquette Freres Biomass of the microalgae Schizochytrium mangrovei and method for preparing same
FR3038914A1 (fr) * 2015-07-17 2017-01-20 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
FR3038913A1 (fr) * 2015-07-17 2017-01-20 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
WO2017012931A1 (fr) * 2015-07-17 2017-01-26 Fermentalg Biomasse de thraustochytrides riche en proteines, procede de culture et utilisations
WO2017012933A1 (fr) * 2015-07-17 2017-01-26 Fermentalg Biomasse de thraustochytrides enrichie en huiles et en proteines, procede de culture et utilisations
CN108587916A (zh) * 2018-05-23 2018-09-28 昆明理工大学 一种共培养单针藻在中性条件下快速絮凝的方法
WO2022124482A1 (ko) * 2020-12-07 2022-06-16 씨제이제일제당(주) 단일 미세조류로부터 단백질 및 오메가-3 지방산을 포함하는 바이오매스를 제조하는 방법 및 이에 의해 제조된 바이오매스

Also Published As

Publication number Publication date
CN106244576A (zh) 2016-12-21
CN103827289A (zh) 2014-05-28
CN102839129A (zh) 2012-12-26
JP2014522635A (ja) 2014-09-08
KR20140019840A (ko) 2014-02-17
JP5894666B2 (ja) 2016-03-30
CN103827289B (zh) 2017-07-21

Similar Documents

Publication Publication Date Title
WO2012175027A1 (en) Methods of mutagenesis of schizochytrium sp and variant strains produced thereof
JP3957196B2 (ja) ドコサヘキサエン酸およびドコサヘキサエン酸を含む化合物
US9476075B2 (en) Oil enriched with arachidonic acid of microorganisms (unicellular fungus Mortierella alpina) and method for the production thereof
Fan et al. Production of high-value products by marine microalgae thraustochytrids
JP2006345866A (ja) アラキドン酸の生成方法
KR102534491B1 (ko) Dha 및, arg 및 glu 아미노산을 갖는, 트라우스토키트리움 속 미세조류 바이오매스의 농축 방법
EP2954072B1 (fr) Biomasse de la microalgue schizochytrium mangrovei et son procédé de préparation
CN103882071B (zh) 一种微生物油及其制备方法
EP3407729A1 (en) Protein containing material biomass and methods of production
FR3031985A1 (fr) Procede d'obtention d'un isolat peptidique issu de la biomasse de microalgues enrichies en proteines
US20210030024A1 (en) Compositions and methods for introduction of odd-chain fatty acids into poultry eggs
WO2020054804A1 (ja) 奇数脂肪酸エステルの製造方法及び培養組成物
JP6429162B1 (ja) ラビリンチュラ類の培養方法
CN113678942B (zh) 小球藻的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12802374

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20137033914

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2014516178

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12802374

Country of ref document: EP

Kind code of ref document: A1